Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) received a notice from NYSE American regarding non-compliance with listing standards due to stockholders equity. The company must submit a plan by May 18, 2024, to regain compliance by October 18, 2025. The notice has no immediate effect on stock trading or business operations.
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) ha ricevuto una notifica dalla NYSE American riguardo alla non conformità agli standard di quotazione a causa dell’equità degli azionisti. L’azienda deve presentare un piano entro il 18 maggio 2024 per riacquisire la conformità entro il 18 ottobre 2025. La notifica non ha effetti immediati sul commercio di azioni o sulle operazioni aziendali.
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) recibió una notificación de NYSE American sobre el incumplimiento de los estándares de cotización debido al patrimonio de los accionistas. La compañía debe presentar un plan antes del 18 de mayo de 2024 para recuperar el cumplimiento antes del 18 de octubre de 2025. El aviso no tiene un efecto inmediato en la negociación de acciones ni en las operaciones comerciales.
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY)는 주주 자본 때문에 상장 기준을 준수하지 않는다는 NYSE American으로부터 통지를 받았습니다. 회사는 2024년 5월 18일까지 규정 준수를 회복하기 위한 계획을 제출해야 하며 2025년 10월 18일까지 이를 달성해야 합니다. 이 통지는 주식 거래나 비즈니스 운영에 즉각적인 영향을 미치지 않습니다.
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) a reçu un avis de NYSE American concernant le non-respect des normes de cotation en raison de l’équité des actionnaires. La société doit soumettre un plan d’ici le 18 mai 2024 pour retrouver la conformité d’ici le 18 octobre 2025. L’avis n’a pas d’effet immédiat sur le commerce des actions ou les opérations commerciales.
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) hat eine Mitteilung von NYSE American erhalten, die auf Nichteinhaltung der Listing-Standards aufgrund des Eigenkapitals der Aktionäre hinweist. Das Unternehmen muss bis zum 18. Mai 2024 einen Plan vorlegen, um die Einhaltung bis zum 18. Oktober 2025 wiederherzustellen. Die Mitteilung hat keine unmittelbaren Auswirkungen auf den Aktienhandel oder die Geschäftstätigkeit.
EMERYVILLE, Calif.–(BUSINESS WIRE)– NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that on April 18, 2024 it received a notice from the NYSE American LLC stating that the Company is below compliance with the NYSE American continued listing standards set forth in Sections 1003(a)(ii) and (iii) of the NYSE American Company Guide pursuant to stockholders equity. The Company must submit a plan by May 18, 2024 advising of actions it has taken or will take to regain compliance with the continued listing standards by October 18, 2025 in order to continue its listing on the NYSE American.
The Company intends to submit a plan to regain compliance to the NYSE American within the prescribed timeframe. The notice from the NYSE American has no immediate effect on the listing or trading of the Company’s common stock, and the common stock will continue to trade on the NYSE American. The notice does not affect the Company’s ongoing business operations or its reporting requirements with the Securities and Exchange Commission (SEC).
About NovaBay Pharmaceuticals, Inc.
NovaBay’s leading product Avenova® Antimicrobial Lid & Lash Solution is often prescribed by eyecare professionals for blepharitis and dry-eye disease and is available directly to consumers through online distribution channels such as Amazon.com. It is clinically proven to kill a broad spectrum of bacteria to help relieve the symptoms of bacterial dry eye, yet is non-irritating and completely safe for regular use. NovaBay offers a full portfolio of scientifically developed products for each step of the standard dry eye treatment regimen, including the Avenova Eye Health Support antioxidant-rich oral supplement, Avenova Lubricating Eye Drops for instant relief, Avenova Warm Eye Compress to soothe the eyes and the i-Chek by Avenova to monitor physical eyelid health. The Avenova Allograft, an amniotic tissue prescription-only product, is available through eyecare professionals in the United States.
NovaBay Pharmaceuticals Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, but not limited to, statements that are based upon management’s current expectations, assumptions, estimates, projections and beliefs. The use of words such as, but not limited to, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar words or expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding the Company’s ability to regain compliance with the continued listing requirements of the NYSE American. These statements involve risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Other risks relating to NovaBay’s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-K filing with the SEC, especially under the heading “Risk Factors,” and in the definitive proxy statement filed by NovaBay with the SEC, especially under the heading “Proposal Five: The Reverse Stock Split Proposal — Risks Relating to the Reverse Stock Split.” The forward-looking statements in this press release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.
Socialize and Stay Informed on NovaBay’s Progress
Like us on Facebook
Follow us on X
Connect with NovaBay on LinkedIn
Visit NovaBay’s Website
Avenova Purchasing Information
For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com
Avenova.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240419003631/en/
NovaBay
Justin Hall
Chief Executive Officer and General Counsel
510-899-8800
Investors
LHA Investor Relations
Jody Cain
310-691-7100
Source: NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals received a notice from NYSE American regarding non-compliance with listing standards due to stockholders equity.
NovaBay Pharmaceuticals must submit a plan by May 18, 2024, to regain compliance with the NYSE American listing standards by October 18, 2025.
The notice from NYSE American has no immediate effect on the listing or trading of NovaBay Pharmaceuticals’ common stock.
The notice from NYSE American does not affect NovaBay Pharmaceuticals’ ongoing business operations or its reporting requirements with the SEC.
NYSE:NBY
NBY Rankings
N/A Ranked by Stock Gains
NBY Latest News
NBY Stock Data
Pharmaceutical Preparation Manufacturing
Manufacturing
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
US
Emeryville
About NBY
novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across
